Delays in Pediatric Evaluation of New and Relevant Cancer Therapies
- PMID: 37977329
- DOI: 10.1016/j.jpeds.2023.113826
Delays in Pediatric Evaluation of New and Relevant Cancer Therapies
Conflict of interest statement
Declaration of Competing Interest M.O. acknowledges active research support from the Rally Foundation for Childhood Cancer Research; Infinite Love for Kids Fighting Cancer; The Jed Ian Taxel Foundation for Rare Cancer Research; Cannonball Kids' cancer; Cookies for Kids' Cancer; the Starr Cancer Consortium; Conquer Cancer, the ASCO Foundation; Handstand Walk for Kids; the Serra Family and the Bianco Family Foundation; Team Caroline; and the National Cancer Institute (NCI) of the National Institutes of Health (NIH) via U01 CA263967. J.B. acknowledges additional grant support from NCIP30 CA008748, NCIP50 CA217694, NIH National Clinical Trials Network Grants U10CA180886 and UM1CA228823, Alex’s Lemonade Stand Foundation, Hyundai Hope on Wheels, Team Connor Foundation, and Curing Kids Cancer. She has served as a paid consultant for Jazz Pharmaceuticals (limited to one pediatric advisory board); an uncompensated consultant on DSMB for Springworks, Merck, and Pfizer; and an uncompensated consultant on pediatric advisory boards for BMS and Eisai. M.O. receives institutional research support for clinical trials from Chugai, Amgen, Karyopharm, and Bayer. J.B. receives institutional research support for clinical trials from Jazz Pharmaceuticals, Lilly, Eisai, Loxo Oncology, Cellectar Biosciences, and Bayer. The authors declare no conflicts of interest.
Comment on
-
Timing for First-in-Minor Clinical Trials of New Cancer Drugs.J Pediatr. 2023 Dec;263:113705. doi: 10.1016/j.jpeds.2023.113705. Epub 2023 Aug 31. J Pediatr. 2023. PMID: 37657661
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
